Exenatide vs Tesofensine
Head-to-head comparison of Exenatide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Exenatide | Tesofensine |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Weight Loss / Reuptake Inhibitor |
| Mechanism | Exenatide binds to and activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | A — FDA Approved | C — Phase II–III Clinical Trials |
| Clinical Status | FDA-approved (Byetta for T2D, 2005; Bydureon for T2D, 2012) | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Common (>=5%): nausea (44% with Byetta, decreases over time), vomiting, diarrhea, dizziness, headache, jitteriness; Hypoglycemia risk increased when combined with sulfonylureas or insulin | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~4186.6 g/mol | ~397.5 g/mol |
| Half-Life | ~2.4 hours (Byetta); ~2 weeks sustained release (Bydureon) | N/A |
Overview
Exenatide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Exenatide — Mechanism & Evidence
Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) originally derived from exendin-4, a peptide found in the saliva of the Gila monster (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA, with Byetta (twice-daily injection) approved in April 2005 and Bydureon (once-weekly extended-release) approved in January 2012, both for type 2 diabetes. Exenatide shares approximately 53% sequence homology with human GLP-1 and is resistant to DPP-4 degradation.
Key claims: Improves glycemic control in type 2 diabetes; Produces modest weight loss; Extended-release formulation provides superior glycemic control.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Exenatide focuses on Metabolic Health, Weight Management, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Exenatide: Common (>=5%): nausea (44% with Byetta, decreases over time), vomiting, diarrhea, dizziness, headache, jitteriness Hypoglycemia risk increased when combined with sulfonylureas or insulin Pancreatitis: rare but reported post-marketing; FDA boxed warning consideration
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesofensine: Triple Monoamine Reuptake Inhibitor in Metabolic Research
Tesofensine triple monoamine reuptake inhibitor metabolic research preclinical evidence mechanisms safety
Ved Srivastava on Peptide Science from Early Days to AI Era
Dr. Ved Srivastava, Chief Scientific Officer at Perpetual Medicines, shares his career in peptide therapeutics. He contributed to drugs like Byetta (exenatide), Bydureon, and Symlin (pramlintide). In a discussion, he covers the field's evolution and 2026 trends including macrocyclic peptides and AI design.